ARS Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

ARS Pharmaceuticals

19/03/2024 11:02

* ARS Pharmaceuticals Inc  SPRY.OQ   SPRY.O  is expected
to show a
fall in quarterly revenue when it reports  results on March 21
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for ARS Pharmaceuticals Inc
is for
a loss of 14 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ARS
Pharmaceuticals Inc is $18.50​, above​ its last closing price
of $9.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.19       -0.18      -0.16     Beat    12.4
 Jun. 30 2023  -0.19       -0.17      -0.18     Missed  -3.6
 Mar. 31 2023  -0.17       -0.17      -0.16     Beat    4.6​
 Dec. 31 2022  -0.13       -0.13      0.77      Beat    692.3
 ​​Sep.        -0.35       -0.35      -0.50     Missed  -40.8
 30 2022                                                
 Jun. 30 2022  -0.50       -0.48      -0.55     Missed  -13.8​
 Mar. 31 2022  -0.53       -0.54      -0.70     Missed  -30.6
 Dec. 31 2021              -0.70      -0.67     Beat    4.6
 This summary was machine generated March 19 at 11:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)